Justin Petrone

A team led by investigators at the University of Oslo hopes to deploy a clinical management platform to enable clinicians to optimize patient therapies.

The company intends to invest its $32 million in IPO proceeds on human resources, R&D, and expanding to international markets, with the US a particular target.

The computers are expected to provide a boost to genomics data sharing efforts and drive the creation of machine-learning tools and associated diagnostics.

The test relies on using quantitative PCR to target genes encoded by prophages — viruses present in Lyme-causing bacteria, which can be easier to detect than the bacteria itself.

The company is positioning the blood-based test as an alternative to invasive chorionic villus sampling, the current standard in Denmark.

Atlas Biolabs, a Berlin-based biotechnology firm, is leading the effort, called Epi-Dx, which is largely funded by the German government. 

The assay is being positioned as an alternative to next-generation sequencing-based approaches, which its creators view as ponderous and pricey.

Called Intervene, the project will use genomic and health data from biorepositories along with machine learning methods to develop new clinical predictive tools.

The service will offer whole-genome sequencing to English patients with rare diseases and cancer as part of routine care.

The decision comes amid a general slowdown in the market, yet also showcases the continued appeal of ancestry-related applications.